FORM	4
------	---

(Print or Type Responses)

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Quirk Gerald E	2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
C/O SYROS PHAR MEMORIAL DRIV		a DIG (20	3. Date of Earliest Transaction (Month/Day/Year) 02/10/2017					X Officer (give title below) Other (specify below) Chief Legal Officer			
CAMBRIDGE, MA		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)		Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D)	Transaction(s)	Ownership Form: Direct (D) or Indirect	Beneficial Ownership
				Code	v	Amount	(A) or (D)	Price		(1) (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)														
of 2.	3. Transaction	3A. Deemed	4.		5. Number 6. Date Exerc		cisable and	7. Title and		8. Price of	9. Number of	10.	11. Nature	
ve Conversion	Date	Execution Date, if	Transact	tion	of		Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect
or Exercise	(Month/Day/Year)	any	Code		Derivativ	ve	(Month/Day	/Year)	Underlying		Security	Securities	Form of	Beneficial
Price of		(Month/Day/Year)	(Instr. 8))	Securities		Securities (Ins		(Instr. 5)	Beneficially	Derivative	Ownership		
Derivative					Acquired	1		(Instr. 3 and 4)					(Instr. 4)	
Security														
					-	d of						1		
													· · /	
					· · · ·						(Instr. 4)	(Instr. 4)		
					and 5)	(5)								
										Amount				
							Date	Expiration		-				
			Cada	v	(1)	m								
-			Code	v	(A)	(D)		-		Shares				
\$ 10.0	02/10/2017		٨		10 000		m	02/00/2027	Common	10 000	\$ 0	40.000	D	
\$ 10.9	02/10/2017		A		40,000		<u>, 1</u>	02/09/2027	Stock	40,000	\$ U	40,000	D	
	 or Exercise Price of Derivative Security 	 Ve Conversion Date v or Exercise (Month/Day/Year) Price of Derivative Security Security Security Security 	ive Conversion Date Execution Date, if or Exercise (Month/Day/Year) any Price of Derivative (Month/Day/Year) Security Security Operation S 10.9 02/10/2017	ve Conversion Date v or Exercise (Month/Day/Year)) Price of Derivative Security	ve Conversion Date v or Exercise (Month/Day/Year)) Price of Derivative Security	ve Conversion Date v or Exercise (Month/Day/Year)) Price of Derivative Security	ve Conversion or Exercise) Price of Derivative Security	ve Conversion Date v or Exercise Price of Derivative Security X 10 9 X 10 9 X 10 9 X 10 9 X 10 9 Date Execution Date, if any (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Instr. 8) Code V (A) (D) (Instr. 3, 4, and 5) (Instr. 8) (Month/Day/Year) (Month/Day/Y	 Ve Conversion Date (Month/Day/Year) Price of Derivative Security A 10.9 A 10.0 A 10.0	vive Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Expiration Date (Month/Day/Year) Amount of Underlying Securities (Instr. 3 and Date Expiration Date * <td>ive Conversion or Exercise (Month/Day/Year) or Exercise (Instr. 3) or Derivative Securities (Instr. 3) or Disposed of (D) (Instr. 3, 4, and 5) or Disposed of (D) (Instr. 3, 4, and 5) or Disposed of (D) (Instr. 3, 4, and 5) or Disposed of (D) (Instr. 3) or Disposed of (D) (Instr. 3)</td> <td> Vec Conversion or Exercise (Month/Day/Year) Price of Derivative Security Price of Derivative Security Security </td> <td> Vec Conversion or Exercise Price of Derivative Security A s 10.9 A 22/10/2017 A 2 40.000 A 40.000 </td> <td>Vive Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) of Derivative Securities Expiration Date (Month/Day/Year) Amount of Underlying Securities Derivative Securities Derivative Securities</td>	ive Conversion or Exercise (Month/Day/Year) or Exercise (Instr. 3) or Derivative Securities (Instr. 3) or Disposed of (D) (Instr. 3, 4, and 5) or Disposed of (D) (Instr. 3, 4, and 5) or Disposed of (D) (Instr. 3, 4, and 5) or Disposed of (D) (Instr. 3)	 Vec Conversion or Exercise (Month/Day/Year) Price of Derivative Security Price of Derivative Security Security 	 Vec Conversion or Exercise Price of Derivative Security A s 10.9 A 22/10/2017 A 2 40.000 A 40.000 	Vive Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) of Derivative Securities Expiration Date (Month/Day/Year) Amount of Underlying Securities Derivative Securities Derivative Securities

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Quirk Gerald E C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE, MA 02139			Chief Legal Officer					

Signatures

/s/ Gerald E. Quirk	02/10/2017
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option becomes exercisable as to 25% of the shares underlying the award on February 10, 2018, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.